Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pearson Plaintiffs Using Shortened Omega-3 Qualified Claim

This article was originally published in The Tan Sheet

Executive Summary

Two of the Pearson plaintiffs plan to incorporate an abbreviated version of FDA's qualified health claim for omega-3 fatty acids and coronary heart disease on dietary supplement labeling.
Advertisement

Related Content

FDA First Amendment Litigation: Will Amarin Case Break The Log Jam?
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
FDA-Drafted Folic Acid Health Claim Disclaimers Ordered By Federal Judge
CFSAN Congressional Reports On DSHEA, Pearson, Strategic Plan Slated
Vitamin B/Vascular Disease Qualified Claim Excludes Specific Nutrient Levels
IVC Omega-3 Supplement With FDA Health Claim Premieres At PLMA
Omega-3/Heart Disease Qualified Supplement Health Claim Allowed
Omega-3/Heart Disease Qualified Supplement Health Claim Allowed
Folic Acid Qualified Health Claims Based On IoM Findings Allowed By CFSAN
SSA Guidance Provides Review Methods, Not Definition

Topics

Advertisement
UsernamePublicRestriction

Register

PS091913

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel